Wipro GE Healthcare on Tuesday said it will invest over Rs 8,000 crore in India over the next five years to increase local manufacturing and research and development (R&D) initiatives.
The strategic investment bolsters the company's local manufacturing footprint to address the growing domestic and international market
Wipro GE Healthcare on Tuesday said it will invest over Rs 8,000 crore in India over the next five years to increase local manufacturing and research and development (R&D) initiatives.
Additionally, locally produced Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured 'In India for the World', the company said in a statement.
Wipro GE Healthcare Managing Director and President & CEO, GE HealthCare South Asia Chaitanya Sarawate said, "As a local partner we are bullish about India's potential and its journey to be 'Atmanirbhar' and a key cog in the resilient global supply chain."